Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease
Levodopa remains the gold standard of treating Parkinson's disease (PD). However, the inevitable complication of levodopa therapy is druginduced dyskinesias, which significantly limits the therapeutic capabilities of this group of drugs and requires treatment adjustment. At the same time, patie...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2020-02-01
|
Series: | Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
Subjects: | |
Online Access: | https://nnp.ima-press.net/nnp/article/view/1268 |
id |
doaj-b75136b9892c49ef87c690e49b984ea6 |
---|---|
record_format |
Article |
spelling |
doaj-b75136b9892c49ef87c690e49b984ea62021-07-29T08:58:41ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422020-02-01121879210.14412/2074-2711-2020-1-87-92960Pharmacogenetics of drug-induced dyskinesias in Parkinson's diseaseA. A. Tappakhov0T. E. Popova1T. G. Govorova2N. A. Shnaider3M. R. Sapronova4M.K. Ammosov North-Eastern Federal University, Ministry of Education and Science of Russia; Yakutsk Research Center for Complex Medical Problems, Ministry of Education and Science of RussiaM.K. Ammosov North-Eastern Federal University, Ministry of Education and Science of Russia; Yakutsk Research Center for Complex Medical Problems, Ministry of Education and Science of RussiaM.K. Ammosov North-Eastern Federal University, Ministry of Education and Science of RussiaV.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Ministry of Health of RussiaProf. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of RussiaLevodopa remains the gold standard of treating Parkinson's disease (PD). However, the inevitable complication of levodopa therapy is druginduced dyskinesias, which significantly limits the therapeutic capabilities of this group of drugs and requires treatment adjustment. At the same time, patients with PD show not only a wide interindividual variability in the response to levodopa treatment, but also differences in the frequency and time to onset of drug-induced dyskinesias. Therefore, genetic predisposition can play an important role in the development of complications of levodopa therapy.The paper reviews modern literature on the impact of mutations in the genes, the products of which are involved in the exchange of levodopa and are capable of provoking or, conversely, levelling the development of drug-induced dyskinesias in order to determine the possibilities of expanding the personalized approach to treating patients with PD.https://nnp.ima-press.net/nnp/article/view/1268parkinson's diseaselevodopadopaminedrug-induced dyskinesias, personalized medicine |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
A. A. Tappakhov T. E. Popova T. G. Govorova N. A. Shnaider M. R. Sapronova |
spellingShingle |
A. A. Tappakhov T. E. Popova T. G. Govorova N. A. Shnaider M. R. Sapronova Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease Nevrologiâ, Nejropsihiatriâ, Psihosomatika parkinson's disease levodopa dopamine drug-induced dyskinesias, personalized medicine |
author_facet |
A. A. Tappakhov T. E. Popova T. G. Govorova N. A. Shnaider M. R. Sapronova |
author_sort |
A. A. Tappakhov |
title |
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease |
title_short |
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease |
title_full |
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease |
title_fullStr |
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease |
title_full_unstemmed |
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease |
title_sort |
pharmacogenetics of drug-induced dyskinesias in parkinson's disease |
publisher |
IMA-PRESS LLC |
series |
Nevrologiâ, Nejropsihiatriâ, Psihosomatika |
issn |
2074-2711 2310-1342 |
publishDate |
2020-02-01 |
description |
Levodopa remains the gold standard of treating Parkinson's disease (PD). However, the inevitable complication of levodopa therapy is druginduced dyskinesias, which significantly limits the therapeutic capabilities of this group of drugs and requires treatment adjustment. At the same time, patients with PD show not only a wide interindividual variability in the response to levodopa treatment, but also differences in the frequency and time to onset of drug-induced dyskinesias. Therefore, genetic predisposition can play an important role in the development of complications of levodopa therapy.The paper reviews modern literature on the impact of mutations in the genes, the products of which are involved in the exchange of levodopa and are capable of provoking or, conversely, levelling the development of drug-induced dyskinesias in order to determine the possibilities of expanding the personalized approach to treating patients with PD. |
topic |
parkinson's disease levodopa dopamine drug-induced dyskinesias, personalized medicine |
url |
https://nnp.ima-press.net/nnp/article/view/1268 |
work_keys_str_mv |
AT aatappakhov pharmacogeneticsofdruginduceddyskinesiasinparkinsonsdisease AT tepopova pharmacogeneticsofdruginduceddyskinesiasinparkinsonsdisease AT tggovorova pharmacogeneticsofdruginduceddyskinesiasinparkinsonsdisease AT nashnaider pharmacogeneticsofdruginduceddyskinesiasinparkinsonsdisease AT mrsapronova pharmacogeneticsofdruginduceddyskinesiasinparkinsonsdisease |
_version_ |
1721250533693456384 |